½ÃÀ庸°í¼­
»óǰÄÚµå
1663811

´ë»çüÇÐ ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç°º°, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Åø ¹× ¼­ºñ½ºº°, ¿ëµµº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, ±â¾÷ À¯Çüº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Metabolomics Market Size, Share, and Growth Analysis, By Product, By Bioinformatics Tools and Services, By Application, By Indication, By End User, By Company Type, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 219 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ë»çüÇÐ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 41¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 46¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 131¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, ¿¹Ãø ±â°£(2025-2032³â)ÀÇ CAGRÀº 13.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

´ë»çüÇÐ ½ÃÀåÀº Á¤¹ÐÀÇ·áÀÇ µµÀÔ Áõ°¡¿Í ¸¸¼ºÁúȯ Áø´Ü ¹æ¹ýÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â Á¦¾à ºÎ¹®ÀÇ R&D ÅõÀÚ Áõ°¡, ºÐ¼® ±â¼ú, ƯÈ÷ ÇÙÀڱ⠰ø¸í ºÐ±¤¹ý ¹× Áú·®ºÐ¼®¹ýÀÇ ¹ßÀüÀ¸·Î ´Ù¾çÇÑ »ýü ½Ã·áÀÇ ´ë»ç »ê¹°À» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù´Â Á¡À» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °íµµÈ­¸¦ ÅëÇØ ´ç´¢º´, ½ÉÀ庴, ¾Ï°ú °°Àº Áúº´°ú °ü·ÃµÈ ´ë»çÀÌ»ó¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁö°í ÀÖ½À´Ï´Ù. °³ÀÎÀÇ ´ë»ç ½Ã±×´Ïó¸¦ ¹àÇô³¿À¸·Î½á ´ë»çüÇÐÀº ¸ÂÃãÇü ÀǷḦ ÃËÁøÇϰí, ´õ ³ªÀº Áúº´ ¿¹Ãø°ú °³º°È­µÈ °ü¸® Àü·«À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¬±¸¸¦ ÅëÇØ »õ·Î¿î ´ë»ç»ê¹°°ú »óÈ£ÀÛ¿ëÀÌ ¹ß°ßµÊ¿¡ µû¶ó Ç¥Àû ¹× ºñÇ¥Àû ´ë»çüÇÐ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí, ÇコÄɾî Çõ½Å¿¡¼­ ´ë»çüÇÐÀÇ Á߿伺Àº ´õ¿í È®°íÇØÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

¼­·Ð

  • Á¶»çÀÇ ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

°³¿ä

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
    • ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ »ê¾÷ ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • ÁÖ¿ä ¼º°ø ¿äÀÎ
  • °æÀïÀÇ Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå ¿¡ÄڽýºÅÛ
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : Á¦Ç°º° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ´ë»çüÇÐ ±â±â
  • ºÐ¸® Åø
    • °¡½º Å©·Î¸¶Åä±×·¡ÇÇ
    • °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ
    • Ãʰí¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ
    • ¸ð¼¼°ü Àü±â¿µµ¿
  • ŽÁö Åø
    • ÇÙÀÚ±â°ø¸í(NMR) ºÐ±¤¹ý
    • Áú·®ºÐ¼®(MS)
    • Ç¥¸é ±â¹Ý Áú·®ºÐ¼®

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Åø°ú ¼­ºñ½ºº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Åø°ú µ¥ÀÌÅͺ£À̽º

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : ¿ëµµº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß
  • Drug Discovery
  • µ¶¼º ½ÃÇè
  • ¿µ¾çÀ¯ÀüüÇÐ
  • ±â´É À¯ÀüüÇÐ
  • ¸ÂÃãÇü ÀÇ·á
  • ±âŸ ¿ëµµ

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : ÀûÀÀÁõº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ¾Ï
  • ½ÉÇ÷°üÁúȯ
  • ½Å°æÁúȯ
  • ´ë»çÀå¾Ö
  • ¼±Ãµ¼º ´ë»çÀÌ»ó
  • ±âŸ ÀûÀÀÁõ

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • Çмú¿¬±¸±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • °è¾à Á¶»ç±â°ü
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : ±â¾÷ À¯Çüº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • Tier 1 Á¦¾àȸ»ç
  • Tier 2 Á¦¾àȸ»ç
  • Tier 3 Á¦¾àȸ»ç

´ë»çüÇÐ ½ÃÀå ±Ô¸ð : Áö¿ªº° & CAGR(2025-2032)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5»çÀÇ ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ÃÖ±Ù ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ °³¿ä
    • ±â¾÷ÀÇ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ÀÇ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâÀÇ Àü³â´ëºñ ºñ±³(2022-2024)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Agilent Technologies, Inc.(US)
  • Thermo Fisher Scientific, Inc.(US)
  • Waters Corporation(US)
  • Bruker Corporation(US)
  • Shimadzu Corporation(Japan)
  • Danaher Corporation(SCIEX)(US)
  • PerkinElmer, Inc.(US)
  • Merck KGaA(Germany)
  • Bio-Rad Laboratories, Inc.(US)
  • Metabolon, Inc.(US)
  • LECO Corporation(US)
  • Human Metabolome Technologies, Inc.(Japan)
  • GL Sciences, Inc.(Japan)
  • Bioocrates Life Sciences AG(Austria)
  • BASF SE(Germany)
  • MS-OMICS(Various locations)
  • Afekta Technologies Ltd.(Finland)
  • DNA Xperts Private Limited.(India)
  • Metabolomic Technologies Inc.(Canada)
  • Kore Technology Ltd.(UK)

°á·Ð°ú Á¦¾È

KSA 25.04.01

Metabolomics Market size was valued at USD 4.1 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 13.12 billion by 2032, growing at a CAGR of 13.8% during the forecast period (2025-2032).

The metabolomics market is poised for significant growth due to its increasing adoption in precision medicine and evolving diagnostics for chronic conditions. Key drivers include rising R&D investments in the pharmaceutical sector and advancements in analytical techniques, particularly nuclear magnetic resonance spectroscopy and mass spectrometry, which enable the comprehensive analysis of metabolites in various biological samples. This sophistication enhances our understanding of metabolic dysregulation associated with diseases like diabetes, heart disease, and cancer. By revealing individual metabolic signatures, metabolomics facilitates tailored medical care, enabling better disease prediction and personalized management strategies. As research uncovers novel metabolites and interactions, the demand for targeted and untargeted metabolomics services is set to rise, solidifying its importance in healthcare innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Metabolomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Metabolomics Market Segments Analysis

Global Metabolomics Market is segmented by Product, Bioinformatics Tools and Services, Application, Indication, End User, Company Type and region. Based on Product, the market is segmented into Metabolomics Instruments, Separation Tools and Detection Tools. Based on Bioinformatics Tools and Services, the market is segmented into Bioinformatics Services and Bioinformatics Tools and Databases. Based on Application, the market is segmented into Biomarker discovery, Drug discovery, Toxicology testing, Nutrigenomics, Functional Genomics, Personalized medicine and Other Applications. Based on Indication, the market is segmented into Cancer, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders, Inborn Errors of Metabolism and Other Indications. Based on End User, the market is segmented into Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End Users. Based on Company Type, the market is segmented into Tier 1 Pharmaceutical Companies, Tier 2 Pharmaceutical Companies and Tier 3 Pharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Metabolomics Market

Metabolite profiling within biological matrices plays a crucial role in discovering biomarkers and advancing personalized medicine. Through metabolomics studies, researchers can identify various biomarkers associated with intricate clinical phenotypes across multiple biological systems. This process is instrumental in the development of tailored medical treatments, focusing on optimizing therapeutic effectiveness while addressing potential toxicity issues. By employing metabolomics, healthcare providers can enhance patient outcomes by ensuring that medical interventions are more aligned with individual biological responses, ultimately paving the way for a more personalized approach to healthcare.

Restraints in the Metabolomics Market

The Metabolomics market faces significant restraints due to the rapid increase in high-volume and heterogeneous data generation, which exacerbates the existing complexity surrounding data management. As life science research produces increasingly intricate and multifaceted data, accurately evaluating high-dimensional information becomes a daunting challenge. This heightened complexity is anticipated to hinder the growth of the Metabolomics market, as researchers and organizations struggle to effectively analyze and interpret the data generated. Consequently, the difficulty in managing such complicated datasets may limit advancements and adoption within the sector, ultimately restraining its potential expansion and innovation.

Market Trends of the Metabolomics Market

The Metabolomics market is witnessing a significant upward trend driven by the expanding applications of biomarkers derived from bioinformatics analyses. As healthcare increasingly pivots towards personalized medicine, the identification of novel biomarkers through metabolomics advancements is becoming essential for in-vitro diagnostics, environmental toxicology assessment, and drug discovery processes. Over the past decade, the "omics" revolution has not only enhanced the technical capabilities of metabolomics but also broadened its relevance across various biomedical domains. This growth trajectory is expected to continue, fueled by the rising demand for precision medicine and integrative approaches to health diagnostics, propelling the Metabolomics market into new horizons of innovation and application.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Metabolomics Market Size by Product & Service & CAGR (2025-2032)

  • Market Overview
  • Metabolomics Instruments
  • Separation Tools
    • Gas Chromatography
    • High-performance Liquid Chromatography
    • Ultra-performance Liquid Chromatography
    • Capillary Electrophoresis
  • Detection Tools
    • Nuclear Magnetic Resonance (NMR) Spectroscopy
    • Mass Spectrometry (MS)
    • Surface-Based Mass Analysis

Global Metabolomics Market Size by Bioinformatics Tools and Services & CAGR (2025-2032)

  • Market Overview
  • Bioinformatics Services
  • Bioinformatics Tools and Databases

Global Metabolomics Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Biomarker discovery
  • Drug discovery
  • Toxicology testing
  • Nutrigenomics
  • Functional Genomics
  • Personalized medicine
  • Other Applications

Global Metabolomics Market Size by Indication & CAGR (2025-2032)

  • Market Overview
  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Inborn Errors of Metabolism
  • Other Indications

Global Metabolomics Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Other End Users

Global Metabolomics Market Size by Company Type & CAGR (2025-2032)

  • Market Overview
  • Tier 1 Pharmaceutical Companies
  • Tier 2 Pharmaceutical Companies
  • Tier 3 Pharmaceutical Companies

Global Metabolomics Market Size & CAGR (2025-2032)

  • North America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
    • US
    • Canada
  • Europe (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Agilent Technologies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Waters Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bruker Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shimadzu Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Danaher Corporation (SCIEX) (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PerkinElmer, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Metabolon, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LECO Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Human Metabolome Technologies, Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GL Sciences, Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bioocrates Life Sciences AG (Austria)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BASF SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MS-OMICS (Various locations)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Afekta Technologies Ltd. (Finland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • DNA Xperts Private Limited. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Metabolomic Technologies Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kore Technology Ltd. (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦